| Compounds | Topics | Title | Date |
|---|---|---|---|
| JWH-133 | liver in rats via experiment | The protective effect of cannabinoid type 2 receptor activation on renal ischemia-reperfusion injury | Aug 2019 |
| The JWH-133 application at three different doses decreased the glomerular and tubular damage. Additionally, in the renal tissue, nuclear factor-kappa-B, tumour necrosis factor alpha, interleukin-1beta, and caspase-3 levels decreased immunohistochemically. Similarly, JWH-133 application decreased the serum tumour necrosis factor alpha, blood urea nitrogen, creatinine, kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, Cystatin C, interleukin-18, interleukin-1beta, interleukin-6, and interleukin-10 levels. | |||
| cannabis | liver in humans via study (n=9000) | Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis | May 2018 |
| Our study revealed that cannabis users (CUs) had decreased prevalence of liver cirrhosis (aPRR: 0.81[0.72-0.91]), unfavorable discharge disposition (0.87[0.78-0.96]), and lower total health care cost ($39,642[36,220-43,387] versus $45,566[$42,244-$49,150]), compared to noncannabis users (NCUs). | |||
| cannabinoids | liver via review | CB2 receptors as new therapeutic targets for liver diseases | Jan 2008 |
| Recent data have unravelled a key role of CB2 receptors during chronic and acute liver injury, including fibrogenesis associated to chronic liver diseases, ischaemia-reperfusion-induced liver injury, and hepatic encephalopathy associated to acute liver failure. This review summarizes the latest advances on the recently identified role of CB2 receptors in the pathophysiology of liver diseases. | |||
| JWH-133 | liver in mice via experiment | Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury | Feb 2007 |
| These findings suggest that oxidative/nitrosative stress and inflammatory stimuli may trigger endocannabinoid production, and indicate that targeting CB2 cannabinoid receptors may represent a novel protective strategy against I/R injury | |||
| THC,JWH-015 | cancer,liver in vitro | Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy | Jul 2011 |
|
Action Pathway: CB2 We found that delta-9-tetrahydrocannabinol (delta-9-THC, the main active component of Cannabis sativa) and JWH-015 (a cannabinoid receptor 2 (CB2) cannabinoid receptor-selective agonist) reduced the viability of the human HCC cell lines HepG2 (human hepatocellular liver carcinoma cell line) and HuH-7 (hepatocellular carcinoma cells), an effect that relied on the stimulation of CB2 receptor. | |||
| cannabinoids | liver,diabetes via review | The Role of Endocannabinoids System in Fatty Liver Disease and Therapeutic Potentials | Jul 2013 |
| There is accumulating evidence on the role CB1 as a key mediator of insulin resistance and liver lipogenesis in both animals and humans. On the other hand, CB2 receptors have been shown to promote inflammation with anti-fibrogenic properties. The pharmacological modulation of the EC system activity for the treatment of metabolic syndrome and NAFLD are promising yet premature. | |||
| cannabinoids | liver via review | The Role of Cannabinoids in the Setting of Cirrhosis | Jun 2018 |
| The endocannabinoid system has been shown to play a role in liver disease, and cirrhosis specifically, with intriguing possible therapeutic benefits. | |||
| cannabinoids | liver via review | Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis. | May 2019 |
| The ECS system is highly upregulated during chronic liver disease and a growing number of studies suggest a mechanistic and therapeutic impact of ECS on the development of liver fibrosis, especially putting its receptors into focus. | |||
| cannabinoids | liver in vitro via experiment | Antifibrogenic role of the cannabinoid receptor CB2 in the liver. | Mar 2005 |
|
Action Pathway: CB2 These data constitute the first demonstration that CB2 receptors are highly up-regulated in the cirrhotic liver, predominantly in hepatic fibrogenic cells. Moreover, this study also highlights the antifibrogenic role of CB2 receptors during chronic liver injury. | |||
| cannabinoids | liver via review | The endocannabinoid system and liver diseases. | May 2008 |
| At present, the CB(1) antagonists represent the most attractive pharmaceutical tool to resolve fat accumulation in patients with non-alcoholic fatty liver disease and to treat patients with cirrhosis, as they may slow the progression of fibrosis and attenuate the cardiovascular alterations associated with the advanced stage of the disease. | |||
| Rimonabant | cholesterol,liver in humans via placebo trial (n=803) | Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. | Mar 2009 |
|
Ingestion Method: 20mg/day In abdominally obese patients with atherogenic dyslipidemia, rimonabant 20 mg significantly improved multiple cardiometabolic risk markers and induced significant reductions in both intraabdominal and liver fat. | |||
| cannabis | liver in humans via survey (n=22366) | Inverse association of marijuana use with nonalcoholic fatty liver disease among adults in the United States. | Oct 2017 |
| Positive In this nationally representative sample, active marijuana use provided a protective effect against NAFLD independent of known metabolic risk factors. The pathophysiology is unclear and warrants further investigation. | |||
| cannabis | liver in humans via study (n=42) | Long-Term Heavy Recreational Cannabis Use and Serum Delta-9-Tetrahydrocannabinol Levels are not Associated with an Impaired Liver Function in Cannabis Dependents. | Sep 2018 |
| These results argue against a relevant harmful impact of chronic cannabis inhalation on the liver function of relatively healthy humans (apart from nicotine dependence). Specifically, the liver function tests were not significantly influenced by THC and THC-COOH levels, both objective markers for the amount and duration of prior cannabis use. | |||
| cannabis | liver via review | Cannabis in liver disorders: a friend or a foe? | Nov 2018 |
| All in all, the recent trends in research, clinical experiences, as well as the legislature, has opened up new avenues towards the widespread clinical application of cannabis and its derivatives as well as modifiers of the components of the endocannabinoid system. More research is required to fully exploit these new evidences. | |||
| cannabis | liver via review | Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis. | Feb 2019 |
| Marijuana use did not increase the prevalence or progression of hepatic fibrosis in HCV and HCV-HIV-coinfected patients. On the contrary, we noted a reduction in the prevalence of NAFLD in marijuana users. Future studies are needed to further understand the therapeutic impact of cannabidiol-based formulations in the management of NAFLD. | |||
| cannabis | liver in humans via study (n=390) | Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients. | Jun 2019 |
| Cannabis consumption may produce a protective effect against liver steatosis in psychosis, probably through the modulation of antipsychotic-induced weight gain. | |||